The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
From the blog
— SMARTEST Trial—
Primary Outcome Measures CD8 TILs density / gross tumor volume (GTV) [ Time Frame: Up to five years ] The primary objective of the study is to demonstrate that low dose cyclophosphamide in combination with sub-ablative radiation can enhance the anti-tumoral immune response compared to sub-ablative radiation alone Secondary Outcome Measures Survival [ Time Frame: Up to[…]
Proton Beam Radiation Therapy Use Increases for Mesothelioma and Lung Cancer
Proton beam radiation therapy is growing in popularity for treating mesothelioma and lung cancer. A study in JAMA Oncology looked at the use of this radiation for treating different types of cancer. There were almost 6 million patients in the study and data shows that proton radiation use tripled from[…]
Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma
A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]
High HITHOC Dosage for Pleural Mesothelioma Improves Survival
High doses of hyperthermic intrathoracic chemotherapy (HITHOC) help pleural mesothelioma patients. A recent study found that when HITHOC is administered at a high dose, survival rates improve and periods of being disease free increase. HITHOC is the use of chemotherapy during surgery and is an experimental treatment for different types[…]
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Primary Objective Efficacy of XmAb20717 as defined by objective response (defined as a complete response [CR] or partial response [PR] on two consecutive occasions ≥4 weeks apart) as determined by an independent radiologist according to RECIST v1.1 (modified RECIST for pleural mesothelioma) Secondary Objective Objective response as determined by an[…]
Two Cytoreductive Surgeries Can Improve Survival for Peritoneal Mesothelioma Patients
If peritoneal mesothelioma patients undergo a second surgery after recurrence, they can improve their survival. Data from a retrospective review from Wake Forest Baptist Medical Center shows that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can be incredibly helpful for peritoneal disease sufferers. For some people, a second surgery has[…]
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Primary Outcome Measures Incidence of Adverse Events (AEs) [ Time Frame: Up to 6 Months ] Time to onset of serious adverse events (SAEs) [ Time Frame: Up to 6 Months ] Time to onset of AEs [ Time Frame: Up to 6 Months ] Time to resolution of AEs [ Time Frame: Up to 6 Months ] Time to resolution of SAEs [ Time Frame: Up to 6[…]
Checkmate 743 Shows Immunotherapy is Better for Mesothelioma Patients Who Cannot Receive Surgery
A clinical trial called Checkmate 743, which looks at the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), shows that the combination can create a better quality of life when compared with the chemotherapy drugs pemetrexed, cisplatin, and carboplatin. Patient reported outcomes were recently reported. People who took Opdivo and Yervoy[…]
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) (MESO-IMMUNE)
Primary Outcome Measures Progression Free Survival assessed locally [ Time Frame: time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause evaluated through the total duration of the study (up to 48 months) ] Progression free survival as assessed by the investigator, defined as the[…]
Skip to content